The dominant left ventricular assist device: lessons from an era

The production and distribution of the HeartWare ventricular assist device has come to an abrupt end, but with this end comes the opportunity to reflect upon lessons learned from its lifespan. Running counter to the standard of evidence‐based practice, the era of the HeartWare ventricular assist dev...

Full description

Saved in:
Bibliographic Details
Published in:ESC Heart Failure 2021-12, Vol.8 (6), p.5551-5554
Main Authors: Alam, Amit, Milligan, Gregory P., Gong, Timothy
Format: Article
Language:English
Subjects:
Blood pressure
Circulatory support
Clinical trials
Design
FDA approval
Heart failure
Heart Failure - surgery
Heart-Assist Devices
Humans
Left ventricular assist device
LVAD
Patients
Stroke
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The production and distribution of the HeartWare ventricular assist device has come to an abrupt end, but with this end comes the opportunity to reflect upon lessons learned from its lifespan. Running counter to the standard of evidence‐based practice, the era of the HeartWare ventricular assist device was marred with fragmented data in relation to its primary counterpart, the HeartMate III. This created an incomplete understanding of devices, limited individualized patient care, and effectively positioned providers to make inferences regarding device superiority. We briefly review pertinent literature on this topic among the most commonly implanted durable devices from the era, detail the inherent limitations of this data, and argue the necessity of randomized clinical trials among novel devices towards the optimization of patient care.
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.13565